Dai, Han

Sirtuin activators and inhibitors: Promises, achievements, and challenges

Dai, H., Sinclair, D. A., Ellis, J. L., & Steegborn, C. (2018) · Pharmacology & Therapeutics

Sirtuins and Resveratrol in MedicineHistone Deacetylase Inhibitors Research

Cited by 463

PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding

Tinworth, C. P., Lithgow, H., Dittus, L., Bassi, Z. I., Hughes, S. E., Muelbaier, M., Dai, H., Smith, I. E. D., Kerr, W. J., Burley, G. A., et al. (2019) · ACS Chemical Biology

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 195

Structural Basis for a Munc13–1 Homodimer to Munc13–1/RIM Heterodimer Switch

Lu, J., Machius, M., Dulubova, I., Dai, H., Südhof, T. C., Tomchick, D. R., & Rizo, J. (2006) · PLoS Biology

Cellular transport and secretionNeuroscience and Neuropharmacology Research

Cited by 132

A Quaternary SNARE–Synaptotagmin–Ca2+–Phospholipid Complex in Neurotransmitter Release

Dai, H., Shen, N., Araç, D., & Rizo, J. (2007) · Journal of Molecular Biology

Cellular transport and secretionNeuroscience and Neuropharmacology Research

Cited by 127

Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs

Anderson, N. A., Cryan, J., Ahmed, A., Dai, H., McGonagle, G. A., Rozier, C., & Benowitz, A. B. (2020) · Bioorganic & Medicinal Chemistry Letters

Protein Degradation and InhibitorsAdvanced Breast Cancer Therapies

Cited by 69